Literature DB >> 22354085

Long-term ketamine and ketamine plus alcohol treatments produced damages in liver and kidney.

M S M Wai1, W M Chan, A Q Zhang, Y Wu, D T Yew.   

Abstract

Ketamine is one of the common recreational drugs used in rave parties and it is frequently taken with alcohol. In spite of this, the potential toxicity of ketamine in liver and kidney has not been fully documented. In this study, ICR mice were treated for periods of 6, 16 and 28 weeks with 30 mg/kg ketamine injected daily intraperitoneally, and together with alcohol (0.5 ml of 10% alcohol for each mouse) during the last 4 weeks of the treatment periods. Our experimental results showed significant damage in liver, including fatty degeneration of liver cells, fibrosis and increase in liver glutamic oxaloacetic transaminase, proliferative cell nuclear antigen and lactate dehydrogenase after 16 weeks of treatment with ketamine. Hydropic degenerations of the kidney tubules were observed as early as 6 weeks of treatment. Long-term ketamine administration (28 weeks) led to atresia of glomeruli in the kidney. Proteinuria was confirmed in the 67% of the ketamine-treated animals after 28 weeks of treatment. It was apparent that ketamine when taken chronically (16 weeks of treatment and thereafter) affected both liver and kidney definitively. The damages in both liver and kidney of these mice were more severe when the animals were treated with both ketamine and alcohol.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22354085     DOI: 10.1177/0960327112436404

Source DB:  PubMed          Journal:  Hum Exp Toxicol        ISSN: 0960-3271            Impact factor:   2.903


  10 in total

1.  Ketamine as a possible cause of cirrhosis in a patient with chronic pain.

Authors:  Roisin Bevan; Denis Burke
Journal:  Frontline Gastroenterol       Date:  2013-12-10

2.  Brain damages in ketamine addicts as revealed by magnetic resonance imaging.

Authors:  Chunmei Wang; Dong Zheng; Jie Xu; Waiping Lam; D T Yew
Journal:  Front Neuroanat       Date:  2013-07-17       Impact factor: 3.856

3.  Environmental enrichment and abstinence attenuate ketamine-induced cardiac and renal toxicity.

Authors:  Xingxing Li; Shuangyan Li; Wenhui Zheng; Jian Pan; Kunyu Huang; Rong Chen; Tonghe Pan; Guorong Liao; Zhongming Chen; Dongsheng Zhou; Wenwen Shen; Wenhua Zhou; Yu Liu
Journal:  Sci Rep       Date:  2015-06-26       Impact factor: 4.379

4.  Trigger mechanisms of secondary sclerosing cholangitis in critically ill patients.

Authors:  Silke Leonhardt; Wilfried Veltzke-Schlieker; Andreas Adler; Eckart Schott; Roland Hetzer; Walter Schaffartzik; Michael Tryba; Peter Neuhaus; Daniel Seehofer
Journal:  Crit Care       Date:  2015-03-31       Impact factor: 9.097

5.  How Ketamine Affects Livers of Pregnant Mice and Developing Mice?

Authors:  Hoi Man Cheung; Tony Chin Hung Chow; David Tai Wai Yew
Journal:  Int J Mol Sci       Date:  2017-05-19       Impact factor: 5.923

6.  The interactive effects of ketamine and ethanol on dopamine expression in the ventral tegmental area of rats.

Authors:  Zhi-Bi Zhang; Tian-Yong Xu; Ding-Yun You; Shuai Yi; Qing Liu; Huifang-Jie Li; Jin-Yun Gu
Journal:  Neuropsychiatr Dis Treat       Date:  2018-08-20       Impact factor: 2.570

Review 7.  Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.

Authors:  Steven P Cohen; Anuj Bhatia; Asokumar Buvanendran; Eric S Schwenk; Ajay D Wasan; Robert W Hurley; Eugene R Viscusi; Samer Narouze; Fred N Davis; Elspeth C Ritchie; Timothy R Lubenow; William M Hooten
Journal:  Reg Anesth Pain Med       Date:  2018-07       Impact factor: 6.288

8.  Multimodal imaging reveals transient liver metabolic disturbance and sinusoidal circulation obstruction after a single administration of ketamine/xylazine mixture.

Authors:  Fang-Hsin Chen; Ching-Fang Yu; Chung-Lin Yang; Yu-Chun Lin; Gigin Lin; Chun-Chieh Wang; Huang-Ping Yu; Jui Fang; Ning-Fang Chang; Ji-Hong Hong
Journal:  Sci Rep       Date:  2020-02-27       Impact factor: 4.379

9.  Inhibitory actions by ibandronate sodium, a nitrogen-containing bisphosphonate, on calcium-activated potassium channels in Madin-Darby canine kidney cells.

Authors:  Sheng-Nan Wu; Hui-Zhen Chen; Yu-Hung Chou; Yan-Ming Huang; Yi-Ching Lo
Journal:  Toxicol Rep       Date:  2015-08-28

10.  Repeated or Continuous Medically Supervised Ketamine Administration Associated with Hepatobiliary Adverse Events: A Retrospective Case Series.

Authors:  Samantha Cotter; Jennie Wong; Neha Gada; Rajdeep Gill; S Christopher Jones; Grace Chai; Daniel Foster; Mark Avigan; Mallika Mundkur
Journal:  Drug Saf       Date:  2021-10-26       Impact factor: 5.606

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.